An official website of the United States government
Home
SEER Inquiry System - Report
Produced: 11/27/2024 1:32 AM
Question 20200061
Inquiry Details
References:
WHO Class Urinary Tumors, 81
Question:
Solid Tumor Rules (2018)/Histology--Bladder: A patient has high-grade papillary urothelial carcinoma with focal glandular and neuroendocrine differentiation followed by carcinosarcoma. Is this one or two primaries? See Discussion.
Discussion:
12-19-19 Transurethral resection of bladder tumor pathology revealed high-grade papillary urothelial carcinoma with focal glandular and neuroendocrine features; Pathology Overread: High-grade papillary urothelial carcinoma with focal glandular and neuroendocrine differentiation. Carcinoma invades muscularis propria pT2.
Histology 8130
01/20/20 to 07/01/20, completed 6 cycles of gemcitabine/cisplatin.
07/30/20 Robotic radical cystoprostatectomy with bilateral pelvic lymph node dissection, open ileal conduit pathology revealed carcinosarcoma, invading perivesical fat, no lymphovascular invasion, negative margins. ypT3bN0M0 disease; Pathology Overread: Carcinosarcoma arising in association with high-grade papillary urothelial carcinoma.
Histology 8980/3 or is there another histology that should be used?
Answer:
The carcinosarcoma is a separate tumor, abstract a new primary per M13. Code this primary to 8980/3.
Based on the information provided, the patient was first diagnosed with papillary urothelial carcinoma and received neo-adjuvant treatment for that specific histologic type. Subsequent resection identified carcinosarcoma arising within the papillary neoplasm. Carcinosarcoma is rare in bladder primaries and is not included in Table 2; however, it is a subtype/variant of sarcoma.
